Natural History Study of C3 Glomerulopathy

Overview

About this study

The aims of this study are to (1) determine the pathological spectrum of C3G, using clinical features available at diagnosis; clinical features over time; renal biopsy results at presentation and (where available) over time and (2) to determine if there are histological features within the renal biopsy that enable us to meaningfully stratify patients into prognostic groups.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Individuals over the age of 1 year old with a clinical diagnosis of C3 glomerulopathy or idiopathic MPGN.
    • We do not want to exclude anyone on the grounds of age, but it is very unusual to see patients diagnosed at ages older than 60 and in very early life.

Exclusion Criteria:

  • Patients who lack the capacity to give informed consent
  • Individuals who do not wish to participate in the study
  • Individuals whose first language is not English and an appropriate interpreter is not available.
  • Inability to obtain informed consent.
  • Individuals with incomplete clinical datasets and/or renal biopsy tissue that is unavailable for analysis

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Fernando Fervenza, M.D., Ph.D.

Open for enrollment

Contact information:

Julie Ray CCRP

(507) 266-5363

Ray.Julie@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20399421

Mayo Clinic Footer